On April 1, 2024 Voyager Therapeutics, Inc. and Peter P. Pfreundschuh entered into a Transition, Separation and Release of Claims Agreement, pursuant to which Mr. Pfreundschuh resigned from his position of Chief Financial Officer and from any and all other positions he holds as an officer of the Company or an officer, employee or director of any of its subsidiaries, effective on April 12, 2024, or such earlier date as may be mutually agreed upon in writing by the Company and Mr. Pfreundschuh (as applicable, such date, the ?Transition Date?), and shall resign from all other positions he holds as an employee of the Company, effective on May 5, 2024 (the ?Separation Date?). In connection with the transition of Mr. Pfreundschuh, on March 27, 2024, the board of directors of the Company appointed Robin Swartz to assume the roles of principal financial officer and principal accounting officer of the Company, effective as of the Transition Date. Ms. Swartz, age 53, has served as the Company?s Chief Operating Officer since February 2022, and previously served as the Company?s Senior Vice President, Business Operations from September 2021 to February 2022 and the Company?s Senior Vice President, Portfolio Management and Patient Engagement from January 2021 to August 2021.

Prior to joining the Company, Ms. Swartz served in positions of increasing responsibility at Genzyme Corporation and Sanofi Genzyme, culminating in her service at Sanofi Genzyme as Senior Vice President, Head of Patient Support Services for Rare Diseases from January 2018 to June 2020 and as Vice President, Head of Global and US Business Operations from June 2015 to December 2017. Her previous roles at Sanofi Genzyme included Chief of Staff to the Executive Vice President and Senior Director, Finance. Ms. Swartz received a B.A. in political science and government from Kenyon College.